These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36737105)

  • 1. Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update".
    Braun J
    Ann Rheum Dis; 2023 Sep; 82(9):e205. PubMed ID: 36737105
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Braun
    Ramiro S; Nikiphorou E; Sepriano A; Ortolan A; Webers C; Baraliakos X; Landewé RB; van der Heijde D
    Ann Rheum Dis; 2023 Sep; 82(9):e206. PubMed ID: 36878690
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twenty Years of SPARTAN: From Inception to Impact (SPARTAN 2023 Annual Meeting Proceedings).
    Ermann J; Deodhar A; Khan MA; Weisman MH; Reveille JD
    Curr Rheumatol Rep; 2024 Mar; 26(3):96-101. PubMed ID: 38214805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question.
    Lukasik Z; Carron P; Webers C
    Best Pract Res Clin Rheumatol; 2023 Sep; 37(3):101869. PubMed ID: 37658017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
    Ortolan A; Webers C; Sepriano A; Falzon L; Baraliakos X; Landewé RB; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):142-152. PubMed ID: 36261247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.
    Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Lavie F; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar AA; Østergaard M; Baraliakos X
    Ann Rheum Dis; 2023 Aug; 82(8):e187. PubMed ID: 35487679
    [No Abstract]   [Full Text] [Related]  

  • 8. Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.
    Siebert S; Marzo-Ortega H
    Ann Rheum Dis; 2023 Aug; 82(8):e185. PubMed ID: 34844925
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physicianreported spondylitis'?' by Siebert and Marzo-Ortega.
    Braun J; Landewé RB
    Ann Rheum Dis; 2023 Aug; 82(8):e186. PubMed ID: 34844931
    [No Abstract]   [Full Text] [Related]  

  • 10. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
    Ramiro S; Nikiphorou E; Sepriano A; Ortolan A; Webers C; Baraliakos X; Landewé RBM; Van den Bosch FE; Boteva B; Bremander A; Carron P; Ciurea A; van Gaalen FA; Géher P; Gensler L; Hermann J; de Hooge M; Husakova M; Kiltz U; López-Medina C; Machado PM; Marzo-Ortega H; Molto A; Navarro-Compán V; Nissen MJ; Pimentel-Santos FM; Poddubnyy D; Proft F; Rudwaleit M; Telkman M; Zhao SS; Ziade N; van der Heijde D
    Ann Rheum Dis; 2023 Jan; 82(1):19-34. PubMed ID: 36270658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Axial spondyloarthritis : Update on management based on the interdisciplinary S3 guidelines on axial spondyloarthritis including early forms and ankylosing spondylitis].
    Kiefer D; Braun J; Kiltz U
    Z Rheumatol; 2022 Apr; 81(3):198-204. PubMed ID: 35113204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiologic approach to axial spondyloarthritis: where are we now and where are we heading?
    Kucybała I; Urbanik A; Wojciechowski W
    Rheumatol Int; 2018 Oct; 38(10):1753-1762. PubMed ID: 30132215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Metrology in Axial Spondyloarthritis: Does It Provide Unique Information in Assessing Patients and Predicting Outcome? Results From the British Society for Rheumatology Biologic Register for Ankylosing Spondylitis.
    Biallas RL; Dean LE; Davidson L; Hollick R; Pathan E; Robertson L; Jones GT; Macfarlane GJ; Rotariu O
    Arthritis Care Res (Hoboken); 2022 Apr; 74(4):665-674. PubMed ID: 33140891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Gladman.
    Landewé RB; Braun J
    Ann Rheum Dis; 2023 Aug; 82(8):e188. PubMed ID: 35487678
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment persistence of tumour necrosis factors and IL-17 inhibitors in axial spondyloarthritis: A multi-center comparative analysis.
    Delépine T; Philippe P; Cailliau E; Houvenagel E; Pascart T; Deprez X; Flipo RM; Letarouilly JG
    Joint Bone Spine; 2022 Nov; 89(6):105416. PubMed ID: 35636707
    [No Abstract]   [Full Text] [Related]  

  • 16. Correspondence on "Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial" by Molto
    Kiltz U; Braun J
    Ann Rheum Dis; 2023 Dec; 82(12):e229. PubMed ID: 34725049
    [No Abstract]   [Full Text] [Related]  

  • 17. The ASAS-OMERACT core domain set for axial spondyloarthritis.
    Navarro-Compán V; Boel A; Boonen A; Mease P; Landewé R; Kiltz U; Dougados M; Baraliakos X; Bautista-Molano W; Carlier H; Chiowchanwisawakit P; Dagfinrud H; de Peyrecave N; El-Zorkany B; Fallon L; Gaffney K; Garrido-Cumbrera M; Gensler LS; Haroon N; Kwan YH; Machado PM; Maksymowych WP; Poddubnyy D; Protopopov M; Ramiro S; Shea B; Song IH; van Weely S; van der Heijde D
    Semin Arthritis Rheum; 2021 Dec; 51(6):1342-1349. PubMed ID: 34489113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to: 'Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli
    Ciurea A; Micheroli R
    Ann Rheum Dis; 2022 Nov; 81(11):e227. PubMed ID: 32933922
    [No Abstract]   [Full Text] [Related]  

  • 19. Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli
    Huang JX; Leong PY; Wei JC
    Ann Rheum Dis; 2022 Nov; 81(11):e226. PubMed ID: 32933918
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on Axial Spondyloarthritis.
    Winkler AE; Miller M
    Mo Med; 2022; 119(1):79-83. PubMed ID: 36033135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.